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InﬂammationHelix B surface peptide (HBSP), derived from erythropoietin, displays powerful tissue protection during kidney
ischemia reperfusion (IR) injury without erythropoietic side effects. We employed cyclization strategy for the
ﬁrst time, and synthesized thioether-cyclized helix B peptide (CHBP) to improve metabolic stability and
renoprotective effect. LC–MS/MS analysis was adopted to examine the stability of CHBP in vitro and in vivo.
The renoprotective effect of CHBP in terms of renal function, apoptosis, inﬂammation, extracellular matrix
deposition, and histological injury was also detected in vivo and in vitro. Antibody array and western blot
were performed to analyze the signal pathway of involvement by CHBP in the IR model and renal tubular
epithelial cells. In this study, thioether-cyclized peptide was signiﬁcantly stable in vivo and in vitro. One dose
of 8 nmol/kg CHBP administered intraperitoneally at the onset of reperfusion improved renal protection
compared with three doses of 8 nmol/kg linear HBSP in a 48 h murine IR model. In a one-week model, the one
dose CHBP-treated group exhibited remarkably improved renal function over the IR group, and attenuated
kidney injury, including reduced inﬂammation and apoptosis. Interestingly, we found that the phosphorylation
of autophagy protein mTORC1 was dramatically reduced upon CHBP treatment. We also demonstrated that
CHBP induced autophagy via inhibition of mTORC1 and activation of mTORC2, leading to renoprotective effects
on IR. Our results indicate that the novel metabolically stable CHBP is a promising therapeutic medicine for
kidney IR injury treatment.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Erythropoietin (EPO) is an endogenous protein that exerts tissue-
protective effects for a wide range of organs, but it causes unfavorable
side effects because of the very high dose requirement necessary to
achieve tissue protection [1]. Helix B surface peptide (HBSP), an 11-
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Zhu).domain of EPO, was recently shown to exert powerful tissue-protective
function in various organs subjected to ischemia reperfusion (IR) injury
by inhibiting inﬂammation and apoptosis [2,3]. However, the 2-minute
plasma half-life of HBSP restricts its application in vivo [2]. Therefore,
structurally optimized transformation of HBSP is required. Similar
to EPO, pyroglutamate helix B surface peptide (pHBSP, also known as
ARA290) was found to attenuate renal IR injury [4]. Interestingly,
pHBSP does not always share the same mechanism with EPO [3].
Although pHBSP also has a plasmahalf-life of only 2min [5], these results
indicated that the artiﬁcial analogs of HBSP produce the same or even
better effects. Cyclization is an efﬁcient approach to stabilize the second-
ary structure of the linear peptide and improve metabolic stability and
potency [6–8]. Therefore, based on the amino acid sequence of HBSP,
we designed and synthesized a series of conformationally constrained
helix B peptides with the goal of increased resistance to proteolytic
degradation, improving renoprotective potency, and decreasing adminis-
trative time and dose.
Optimizing kidneypreservation is a primary issue in transplantation,
particularly relative to new donor sources, such as expanded criteria
2307C. Yang et al. / Biochimica et Biophysica Acta 1842 (2014) 2306–2317donors and donation after cardiac death. Kidneys from these donors are
highly sensitive to IR injury, which is a major cause of delayed graft
function and affects both short- and long-term graft survivals. However,
no potent therapy is conﬁrmed thus far. Overwhelming evidence has
suggested that kidney IR injury is an inﬂammatory disease mediated
by innate and adaptive immunity [9]. Apoptosis, inﬂammation [10],
and complement cascades [11] are all initiated by kidney IR injury.
Imbalance of tissue-protective regulatory T (Treg) cells and tissue-
destructive T helper 17 (Th17) cells, caused by the imbalance of pro-
and anti-inﬂammatory cytokines in themilieu, has also been conﬁrmed
in injured allografts resulting from IR [12].
Autophagy, an evolutionarily conserved process of lysosome-
dependent turnover of damaged proteins and organelles, is present in
normal kidneys and upregulated in response to stress, such as IR injury
[13]. Autophagy is believed to exert a beneﬁcial role in IR injury as
rapamycin, anmTOR inhibitor and potent inducer of autophagy, amelio-
rates tubular injury and reduces renal dysfunction [14]. Many recent
ﬁndings suggest that glucose deprivation during IR triggers autophagy
via the activation of AMP-dependent protein kinase (AMPK) and inhibi-
tion ofmTOR in thehearts [15]. In addition, the PI3K–Akt signalingpath-
way has also been proven to play an important role in autophagy [13].
In the current paper, we describe the design and synthesis of a novel
cyclic analog of HBSP, designated as CHBP. Furthermore, we demonstrat-
ed that CHBP exhibited better metabolic stability and renoprotective
effects than its linear counterpart. Given that HBSP has been elucidated
to protect the kidney from IR injury via PI3K/Akt signaling as well as
signal transducer and activator of transcription (STAT) [3,16], we postu-
late that this novel CHBP might exert its renoprotective function by sim-
ilar mechanisms. Moreover, we found that reduced apoptosis and
inﬂammatory responsesmight be associatedwith IR-induced autophagy.
2. Materials and methods
2.1. Peptide synthesis
The synthetic procedure for the cyclized peptides (Fig. 1A) and
additional details on themethods and circular dichroism (CD)measure-
ments are provided in the Supplementary material.
2.2. Three different synthetic cyclopeptides
Thioether-cyclized peptide, CHBP: ESI-MSm/z: calculated 1416.7
(M + H)+, found 1416.8; tR = 15.012 min (10%–90% of solvent B in
30 min, purity 98.86%); tR = 25.123 min (10%–90% of solvent C in
30 min, purity 98.44%).
(R)-Conﬁgured sulfoxide-cyclized peptide: ESI-MS m/z: calculated
1432.6 (M+ H)+, found 1432.7; tR = 14.011 min (10%–90% of solvent
B in 30 min, purity 99.33%); tR = 24.993 min (10%–90% of solvent C in
30 min, purity 99.82%).
(S)-Conﬁgured sulfoxide-cyclized peptide: ESI-MS m/z: calculated
1432.6 (M+ H)+, found 1432.7; tR = 14.044 min (10%–90% of solvent
B in 30 min, purity 98.43%); tR = 25.025 min (10%–90% of solvent C in
30 min, purity 99.00%).
2.3. Stability in the plasma and hepatocytes
The stabilities of CHBP and HBSP were detected using blank human
plasma from healthy volunteers and hepatocyte solution (In Vitro Tech-
nologies, Victoria, Australia). Details are available in the Supplementary
material.
2.4. In vivo metabolic stability
The metabolism of CHBP and HBSP was detected in vivo using
Sprague–Dawley rats, which could supply sufﬁcient blood samplesfor detection at successive time points in the same individual. Details
are available in the Supplementary material.2.5. Kidney IR injury
Male BALB/cmice (weighing 20–25 g)were obtained from Shanghai
Slac Lab Animal, Co., Ltd., and bred in an experimental animal room
of SPF grade. All animal procedures were performed according to the
guidelines of the Care and Use of the Laboratory Animal Ethical
Commission of Fudan University. The kidney IR model was established
as previously described [3], and details are outlined in the Supplemen-
tary material.
To select an optimal peptide from the three cyclized peptides, mice
were given a kidney IR injury and randomly divided into six groups
(n = 6) according to different treatments: (1) IR group: PBS; (2) HBSP
one dose group: one dose of 8 nmol/kg; (3) HBSP three dose group:
three doses of 8 nmol/kg administered at the onset, 6 h, and 12 h post-
reperfusion; (4) thioether-CHBP group: one dose of 8 nmol/kg; (5) (R)-
sulfoxide-CHBP group: one dose of 8 nmol/kg; and (6) (S)-sulfoxide-
CHBP group: one dose of 8 nmol/kg. All agents were intraperitoneally
(i.p.) injected at the onset of reperfusion, except the third group. Animals
were ethically sacriﬁced at 48 h post-reperfusion.
To evaluate the renoprotective effect and mechanism of CHBP, mice
were randomly divided into two groups (n = 36): (1) IR group: IR
injury with PBS i.p. injected; and (2) CHBP group: IR injury with one
dose of 8 nmol/kg CHBP i.p. injected at the onset of reperfusion. Animals
were ethically sacriﬁced at 6 h, 12 h, 24 h, 48 h, 5 d, and 7 d post-
reperfusion (n = 6 for each time point). Whole blood and kidney sam-
ples were acquired and prepared for further examination as previously
described [3].2.6. Extracellular matrix deposition assay
The deposition of the extracellular matrix was evaluated by Sirius
Red (collagen speciﬁc dye) staining, as previously described [10]. Details
are available in the Supplementary material.2.7. Histological assessment
Hematoxylin and eosin (H&E) staining was performed to assess
histological injury. Details are available in the Supplementary material.2.8. In situ end labeling (ISEL) apoptotic cells
ISEL apoptotic cells were detected using a TUNEL Apoptosis Detec-
tion Kit (Millipore,MA, USA). Details are available in the Supplementary
material.2.9. Immunohistochemistry
Immunohistochemical staining of myeloperoxidase (MPO) and
cleaved caspase-3, which recognizes the 17 kDa active subunit, was per-
formed on parafﬁn sections using a DAKO ChemMate EnVision
Detection Kit (DAKO). Details are available in the Supplementary
material.2.10. Enzyme-linked immunosorbent assay (ELISA) of complement 3 (C3)
C3 was assayed in duplicate using sandwich ELISA (Quantikine Kit
for Mice Complement 3 Immunoassay; GenWay, San Diego, CA, USA).
The sample preparation and procedure were performed according to
the manufacturer's instructions.
Fig. 1. Peptide synthesis andmetabolic stability.Metabolically stabilized structuralmodiﬁcation on theHBSP of EPO by thioether and sulfoxide cyclization (A). Thioether-CHBP remarkably
improved stability in the human plasma and human hepatocytes in vitro (B–G), as well as in rats in vivo (H).
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The mRNA expression of TNF-α, IL-6, IL-10, IL-17A, IL-17F, RORγt,
and Foxp3 was measured by real-time qPCR. Details are available in
the Supplementary material.
2.12. Tubular epithelial cell (TEC) stimulation and apoptosis detection
Mice renal proximal TECs were cultured and incubated with HBSP
(1 μM) or CHBP (1 μM) for 12 h, and stimulated with 50 μM H2O2
(Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) for 45 min.
PBS was used as a positive control, and normal TEC without any stimu-
lation was used as a negative control. After washing and changing the
medium, the TEC was cultured for 24 h with PBS, HBSP, or CHBP. Cell
apoptosis was detected by an Annexin V-FITC Apoptosis Detection Kit
(Merck, Darmstadt, German) as mentioned previously [17]. The exper-
iment was repeated at least three times.
2.13. Antibody array
A PathScan Intracellular Signaling Array Kit (Chemiluminescent
Readout, Cell Signaling Technology) was used for the simultaneous
detection of 18 phosphorylated or cleaved signaling proteins in the
kidney. Details are available in the Supplementary material.
2.14. Western blot analysis
Membrane proteinswere separated on SDS-polyacrylamide gels and
transferred to polyvinylidene diﬂuoride membranes. The membranes
were blocked with 5% milk and incubated overnight with anti-beclin-
1, anti-p-Akt (Ser473), anti-Akt, anti-p-mTOR (Ser2448), anti-p-mTOR
(Ser2481), anti-mTOR, anti-p-p70S6K (Thr389), anti-p70S6K, anti-
LC3, anti-raptor, anti-rictor (Cell Signaling, Beverly, MA, USA, 1:1000),
and anti-β-actin (Abcam, Cambridge, UK, 1:10,000) antibodies. The
results were analyzed as previously described [18].
2.15. Statistical analysis
Data are presented as mean ± standard deviation (SD). Statistical
analysis (SPSS 18.0 software, SPSS Inc, Armonk, NY, USA)wasperformed
with the two-tailed independent Student's t-test after the demonstra-
tion of homogeneity of variance with the F test or one-way ANOVA for
more than two groups. The Scheffe test was used for post-hoc analysis.
Statistical signiﬁcance was set as p b 0.05.
3. Results
3.1. Thioether cyclization of HBSP remarkably improved the metabolic
stability
Peptide cyclization provides an effective approach to tackle the
problems of poor cell permeability, secondary structure instability,
and in vivo proteolysis; these problems severely compromise peptides
as successful therapeutic agents [19]. In the present study, we applied
the head-to-tail cyclization strategy to HBSP for improved stability and
activity. Brieﬂy, the peptide backbone was constrained via cyclization
through main chain to main chain linkages, herein using thioether,
(R)-sulfoxide, and (S)-sulfoxide connectors (Fig. 1A), which have been
reported in our previous studies to achieve proteolytic resistance with
activity retention or enhancement [7,8]. The synthetic procedures of
cyclized peptides are shown in the Supplementary material (Fig. S1).
Preliminary kidney IR injury assay indicated that the thioether-cyclized
peptide (designated as CHBP) displayed a superior renoprotective effect
to the sulfoxide versions. Therefore, the newly synthesized CHBP was
chosen to evaluate in vitro and in vivo metabolic stabilities in compari-
son with the native linear peptide HBSP.Since peptides are usually degraded mainly in the plasma by prote-
olysis, we prepared CHBP and HBSP in the human plasma at two differ-
ent concentrations and analyzed the stability and half-life time using
LC–MS/MS. As expected, HBSPwas rapidly degraded in the human plas-
ma at 0.2 and 1 μM, and the half-life timewas 9.97 and 9.45min, respec-
tively (Fig. 1B and C). By contrast, CHBP was detected as 100% original
peptide in the plasma during the experimental span of 300 min
(Fig. 1D and E), indicating that the thioether-cyclized peptide CHBP
was signiﬁcantly stable in the human plasma. We also examined the
stability of CHBP and HBSP in the cytochrome metabolism system
using human hepatocytes. As shown in Fig. 1F and G, CHBP exhibited
a 2.5-fold longer half-life than the corresponding linear peptide HBSP
at the same concentration (Fig. 1F and G), suggesting that thioether
cyclization protected the cyclic peptide CHBP from degradation by
metabolic enzymes. Furthermore, CHBP also showed a remarkably
slow metabolism in vivo (Fig. 1H). Taken together, we obtained a
novel thioether-cyclized peptide CHBP, which was characterized by
high resistance to proteolytic degradation and longer half-life time
compared with HBSP.
3.2. CHBP stabilized the secondary structures of HBSP
To investigate whether cyclization affects the secondary structure of
the cyclic peptide relative to the native peptide, we measured the CD
spectra of the linear peptide HBSP and cyclized peptide CHBP. Two
solvent systems were employed, namely, 40% acetonitrile (for solubili-
ty) in PBS buffer, and 50% triﬂuoroethanol (TFE) in PBS buffer. TFE is
usually employed to induce the formation of the secondary structures
of the peptide in aqueous solution. The observed positive maximum
near 190 nm and double negative minima at 206 nm and 220 nm char-
acterize anα-helix structure (Fig. S2, Table S1) [20]. The CD spectra sug-
gested that the helix B surface peptide HBSP was apt to form α-helix,
that thioether cyclization distinctly stabilized the α-helix geometry.
3.3. CHBP improved renal function and histological structure in the kidney
IR injury model
To evaluate the renoprotective ability of CHBP, we analyzed the
levels of blood urea nitrogen (BUN) and serum creatinine (Scr), which
are two indicators of renal function. In a kidney ischemia and 48 h
reperfusion murine model, CHBP treatment led to much lower levels
of BUN and Scr compared with HBSP treatment (Fig. 2A and B). In a
7 d reperfusion murine model, BUN peaked at 48 h post-reperfusion,
whereas the Scr level gradually increased until 48 h post-reperfusion
and signiﬁcantly decreased thereafter. These ﬁndings indicate that
48 h post-reperfusion marked the climax of kidney IR injury. CHBP ad-
ministration at the onset of reperfusion dramatically reduced the levels
of BUN and Scr at 6, 12, 24, and 48 h post-reperfusion (Fig. 2C and D).
Renal histological assessment in each group was performed by H&E
staining (Fig. 2E). Semi-quantitative analysis using a histological scoring
system revealed that the tissue structure in the CHBP-treated groupwas
well protected, with mild tubular dilation and interstitial edema, fewer
protein casts in tubular lumens, and cellular inﬁltration,without tubular
epithelial vacuolation or detachment frequently found in the CHBP-
untreated group (Fig. 2F). In addition, we compared the in vivo
renoprotective efﬁciency of CHBP with that of HBSP in a kidney ische-
mia and 15 d reperfusion murinemodel by extracellular matrix deposi-
tion examination. Both HBSP and CHBP were administered with only
one dose (8 nmol/kg) at the onset of reperfusion. Extracellular matrix
deposition in the kidney was evaluated by Sirius Red staining, which
intercalated tertiary grooves in the structures of collagens I and III
presented in pink under white light in the IR model. Sirius Red staining
was mainly located in the tubulointerstitium, as shown by arrows
(Fig. 2G). The CHBP group demonstrated signiﬁcantly lowered staining
compared with both the HBSP and IR groups in post-reperfusion
kidneys (Fig. 2H).
Fig. 2.Renal function in the screening of CHBP. In a kidney ischemia and 48h reperfusionmurinemodel, CHBP causedmuch lower levels of BUN and Scr comparedwithHBSP (A, B). In a 7 d
reperfusion murinemodel, CHBP administration at the onset of reperfusion signiﬁcantly reduced the levels of BUN and Scr at 6, 12, 24, and 48 h post-reperfusion (C, D). Moreover, CHBP
signiﬁcantly ameliorated renal histological injury detected by H&E staining (E, F). The in vivo renoprotective efﬁciency of CHBPwas compared with that of HBSP in a kidney ischemia and
15 d reperfusionmurinemodel by extracellularmatrix deposition examination (G). The CHBP group demonstrated signiﬁcantly lowered Sirius Red staining comparedwith both theHBSP
and IR groups in post-reperfusion kidneys (H). Mean ± SD, *p b 0.05; **p b 0.01, n = 6.
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Considering that the protection of HBSP during kidney IR injury is
mediated by two main processes: interference with apoptosis and
inﬂammation, we detected them in the CHBP-treated IR model to
explore the underlying mechanisms.
Apoptotic cells were determined by ISEL and active caspase-3
immunostaining in renal tissue sections (Fig. 3A and C). In the
CHBP-treated group, ISEL + cells (Fig. 3B) and active caspase-3+
cells (Fig. 3D) were dramatically reduced in the kidney post-
reperfusion.Fig. 3. Apoptotic cells in the kidney. ISEL + apoptotic cells were signiﬁcantly decreased by CHB
**p b 0.01, n = 6.3.5. CHBP decreased the inﬂammatory responses in kidney IR injury
MPO+ neutrophils were detected by immunostaining to determine
the effect of CHBP on inﬂammatory cell inﬁltration in the kidney
(Fig. 4A). Most MPO + cells in the kidney were located in the vascular
lumens and interstitial areas with polymorphic nucleus. MPO + cells
gradually increased and peaked at 48 h post-reperfusion in the IR
group, but signiﬁcantly decreased in the CHBP-treated group at the
corresponding time points (Fig. 4B). These ﬁndings suggest that CHBP
signiﬁcantly inhibited neutrophils recruited to the injured tissue,
thereby prohibiting the inﬂammatory responses.P post-reperfusion (A, B), as well as active caspase-3+ cells (C, D). Mean ± SD, *p b 0.05;
Fig. 4. Inﬂammatory responses in the kidney. MPO + cells were signiﬁcantly reduced in the kidney by CHBP (A, B). In addition, the expression of C3 in the serum was signiﬁcantly
increased by CHBP at 12, 24, and 48 h post-reperfusion, indicating the ameliorated activation of C3. The expression of C3 in the kidney was signiﬁcantly reduced at 24 and 48 h post-
reperfusion in the CHBP-treated group, which revealed low local synthesis or deposition (C, D). Mean ± SD, *p b 0.05; **p b 0.01, n = 6.
2312 C. Yang et al. / Biochimica et Biophysica Acta 1842 (2014) 2306–2317The complement system actively regulates various steps of an
inﬂammatory response. The activation of the complement system
plays an important role in IR injury. The C3 level in both the serum
and kidney was examined by ELISA. Compared with the CHBP-treated
group, the expression of C3 in the serum signiﬁcantly decreased in the
IR group at 12, 24, and 48 h with increased expression in the kidney at
24 and 48 h-post reperfusion. These results indicate the activation of
complement, and more deposition or local synthesis in the kidney
(Fig. 4C and D).
We further determined the mRNA expression of inﬂammatory
cytokine and transcription factors. In the CHBP-treated group, TNF-α
was signiﬁcantly decreased by 83%, 86%, and 93% at 6, 24, and 48 h
post-reperfusion, respectively (Fig. 5A), and IL-6 was signiﬁcantly
decreased by 84%, 93%, and 85% at 6, 12, and 48 h post-reperfusion,
respectively (Fig. 5B). The mRNA levels of cytokines and transcription
factors of Treg and Th17 in the kidney were examined. IL-10 was
remarkably upregulated at 6 h, 48 h, and 7 d post-reperfusion
(Fig. 5C), and Foxp3 signiﬁcantly increased at 6 h, 24 h, 48 h, and 5 d
in the CHBP group (Fig. 5D). Furthermore, IL-17A and IL-17F, two
important cytokines for Th17 cells, were signiﬁcantly inhibited byCHBP (Fig. 5E and F), and RORγt signiﬁcantly decreased at 12, 24, and
48 h post-reperfusion in the CHBP group (Fig. 5G).
3.6. CHBP induced autophagy in the IR-injured kidney
To elaborate signal transduction when treated with CHBP in the
kidney IR injury model, antibody array was performed using kidney
tissues at 48 h post-reperfusion (Fig. 6A). Interestingly, our results
show that phosphorylated STAT3 and AMPKα signiﬁcantly increased
in the CHBP-treated group (Fig. 6B and C), and the phosphorylation of
mTORC1 at S2448 signiﬁcantly decreased (Fig. 6D). These proteins are
related to autophagy [21,22].
Given that autophagy is demonstrated to be a renoprotective mech-
anism in IR injury, we also detected whether the renoprotective func-
tion of CHBP is mediated by autophagy. Our results depict a signiﬁcant
concurrent increase in the LC3-II/LC3-I ratio (autophagy) and beclin-1
in the CHBP-treated group (Fig. 7A–C), suggesting that CHBP might
induce autophagy to exert its renoprotective functions. Considering
that the mammalian target of rapamycin (mTOR) is a critical mediator
of autophagy [23] and exists in two distinct complexes (i.e., mTORC1
Fig. 5.CHBPmodulated themRNA expression of inﬂammatory cytokine and transcription factors. In the CHBP-treated group, TNF-α and IL-6were signiﬁcantly decreased at 6, 24, and 48h
post-reperfusion (A, B). IL-10 and Foxp3were remarkably upregulated at 6 h, 48 h, and 7 d, or 6 h, 24 h, 48 h, and 5 d post-reperfusion, respectively (C, D). IL-17A, IL-17F, and RORγt were
signiﬁcantly inhibited by CHBP (E–G). Mean ± SD, *p b 0.05; **p b 0.01, n = 6.
2313C. Yang et al. / Biochimica et Biophysica Acta 1842 (2014) 2306–2317and mTORC2), we evaluated the expression of mTORC after treatment
with CHBP in the kidney IR model. Under CHBP treatment, mTOR
complexes were differentially regulated in which the phosphorylation
of mTORC1 at serine 2448 was inhibited, whereas the phosphorylation
of mTORC2 at serine 2481 was increased (Fig. 7A, D, and E). Raptor, a
component of mTORC1, was elevated by CHBP (Fig. 7A and F). Rictor,
which is critical for mTORC2, was also increased by CHBP (Fig. 7A and
G). To further analyze the role of mTORC1, we examined the activation
of p70s6 kinase (phosphorylation at Thr389), a direct downstream
target of mTORC1. Our results show that the p70s6 kinase wassigniﬁcantly reduced by CHBP treatment (Fig. 7A andH). Akt, the down-
stream target ofmTORC2,was also activated via phosphorylation at ser-
ine 473 by Rictor (Fig. 7A and I). These results demonstrate, for the ﬁrst
time, that the novel CHBP could induce autophagy to exert
renoprotective functions in the kidney IR model, and indicate that
CHBP-induced autophagy was mainly through mTOR signaling.
In some conditions, autophagy is deﬁned to be a cell survival mech-
anism that suppresses apoptosis. To further conﬁrm the autophagy in-
duction and anti-apoptotic effects of CHBP, we used an H2O2-induced
renal TEC injury model in vitro. CHBP signiﬁcantly inhibited apoptosis
Fig. 6. Change in signal transduction induced by CHBPwas screened by antibody array using kidney tissues at 48 h post-reperfusion (A). Phosphorylated STAT3 and AMPKα signiﬁcantly
increased in the CHBP-treated group (B, C), and the phosphorylation of mTORC1 at S2448 signiﬁcantly reduced (D). The protein data were expressed as the corrected volume density
against the mean volume density of three positive controls (blue circles) in the same well. Three dots at the bottom represent the negative controls (green circles) in the bottom right
corner. Mean ± SD, *p b 0.05; **p b 0.01, n = 6.
2314 C. Yang et al. / Biochimica et Biophysica Acta 1842 (2014) 2306–2317and HBSP (Fig. 8A and B). In addition, CHBP revealed a stronger
autophagy-inducing effect in terms of the higher expression of LC3-
II/LC3-I (Fig. 8C). The in vitro experiment proved that CHBP could
induce autophagy and suppress apoptosis.
4. Discussion
In this paper, we report for the ﬁrst time a novel CHBPwith improved
metabolic stability and renoprotective potency. The functional motif of
CHBP was derived from HBSP, but the peptide sequence was cyclized by
a redox stable thioether linkage to gain proteolytic resistance and optimal
geometric stabilization. CHBP demonstrated improvedmetabolic stability
both in vitro (plasma and hepatocytes) and in vivo. Furthermore, some
helicity was observed for linear peptide HBSP and the cyclization stabi-
lized the α-helix structure of CHBP according to CD studies.
Given its short plasma half-life, linear HBSP needs to be frequently
administered with high doses to achieve tissue-protective effects [24].
For example, in rodent peripheral nerve injury models, 30 μg/kg
(23.5 nmol/kg) HBSP was administered ﬁve times i.p. at 2 d intervals,
followed by once a week, showing reduced inﬂammation and long-
term relief of allodynia [25]. In another murine nerve injury model,
HBSP presented neural protective functions with a dose over tenfold
of ours and ﬁve doses per week [26]. In addition, Brines et al. examined
different doses of HBSP in a murine kidney IR injury model. They found
that both 0.8 and 8 nmol/kg are most effective, but three administra-
tions of HBSP are still needed [2]. For these deﬁciencies, the thioether-
cyclized CHBP with constrained conformation confers a prolonged
half-life time and enhanced potency to the cyclic peptide according to
the mechanism of circular polypeptides [27]. The less extracellular
matrix deposition in the post-reperfused kidney by CHBP comparedwith that by HBSP suggests that this long-acting CHBP could ameliorate
IR injurywith better outcomes,which beneﬁted from its stability. In this
study, only one dose of CHBP exerted persistent renal protection
throughout the one week reperfusion injury in vivo.
In addition, for theﬁrst time,we identiﬁed CHBP-induced autophagy
in the IR-injured kidney by upregulation of the LC3-II/I ratio and
increased expression of beclin-1. HBSP has been demonstrated to be
involved in the processes of apoptosis and inﬂammation. However,
autophagy is deﬁned to be a cell survival mechanism, and has been
shown to be correlated with apoptosis and inﬂammation. Our results
show that mTORC, which is the key regulator of autophagy [28], was
consistently induced by CHBP. Furthermore, our study depicted possible
signaling pathways, including mTOR regulation and AMPK activation,
which link CHBP-induced autophagy with apoptosis and inﬂammatory
responses. AMPK is a stress-activated kinase that acts to resort ATP
levels back to homeostasis [29], and activation of AMPK plays an impor-
tant role in protecting the kidney against IR injury [30]. In our study, the
activated AMPK by CHBP suggests that CHBP promoted energy produc-
tion through higher ATP levels under the condition of ATP depletion
during IR injury. AMPK activates TSC2, which inhibits mTORC1 [31].
Moreover, CHBP treatment reduced phosphorylated mTOR (Ser2448)
and p70s6 kinase (Thr389). These results suggest that the AMPK/
mTORC1 pathway was involved in CHBP-mediated autophagy.
Interestingly, both AMPK and Akt are key regulators of kidney func-
tion and play critical roles in apoptosis [3,32]. However, potential
crosstalk between the two under physiological or pathological condi-
tions is unclear. According to our results, mTOR (mTORC1) was activat-
ed by Akt, but inhibited by AMPK via the phosphorylation of TSC2. Akt is
also a downstream protein, which is phosphorylated at Ser473 by the
activation of mTORC2. The convergence of the two at the level of mTOR
Fig. 7. CHBP-induced autophagy was determined by western blot in the IR-injured kidney (A). A signiﬁcant concurrent increase was observed in the LC3-II/LC3-I ratio (autophagy) and
beclin-1 in the CHBP-treated group (B, C). Under CHBP treatment, mTOR complexes were differentially regulated in which the phosphorylation of mTORC1 at serine 2448 was inhibited,
whereas the phosphorylation of mTORC2 at serine 2481 increased (D, E). Raptor and Rictor were elevated by CHBP (F, G). The p70s6 kinase (phosphorylation at Thr389), a direct
downstream target of mTORC1, was signiﬁcantly reduced by CHBP treatment (H). Akt, the downstream target of mTORC2, was also activated via phosphorylation at serine 473 (I).
Mean ± SD, *p b 0.05; **p b 0.01, n = 6.
Fig. 8. CHBP protected renal TECs against H2O2-induced apoptosis and promoted autophagy. CHBP andHBSP signiﬁcantly inhibited apoptosis of renal TECs (A, B). However, CHBP revealed
a stronger autophagy-inducing effect in terms of the higher expression of LC3-II/LC3-I (C). Mean ± SD, *p b 0.05; **p b 0.01, n = 6.
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Fig. 9. Schematic illustration of the pathway mediated by CHBP. CHBP-induced autophagy is mediated by inhibition of mTORC1 and activation of mTORC2.
2316 C. Yang et al. / Biochimica et Biophysica Acta 1842 (2014) 2306–2317may serve as a critical avenue for the crosstalk between AMPK and Akt
during pathophysiological adaption. Consequently, CHBP activated
mTORC2–Akt and inhibitedmTORC1 by activating AMPK (Fig. 9). How-
ever, the precise regulatorymechanism betweenmTORC1 andmTORC2
needs further investigation.
Indeed, autophagy plays key roles in the immune systems [33]. In
our study, CHBP signiﬁcantly upregulated the mRNA expression of
Foxp3 and IL-10, suggesting an increase in Treg and promoted immuno-
regulation by CHBP in kidney IR injury. IL-17A and IL-17F initiate inﬂam-
matory responses by increasing the expression of pro-inﬂammatory
cytokines and chemokines, regulating neutrophil inﬁltration [34],
whichwas signiﬁcantly reduced by CHBP, decreasing neutrophil inﬁltra-
tion, and alleviating kidney histological lesions. RORγt was also remark-
ably reduced in the kidney by CHBP at the peak of IR injury. Therefore,
CHBPupregulated Treg and inhibited Th17 in the kidney during IR injury
to modulate the adaptive immunity in terms of restoring the Treg/Th17
balance.
We screened signaling proteins in the kidney at 48 h post-reperfusion
when the injury reached its peak. The results reveal that CHBP activated
STAT3 and AMPKα, but inhibitedmTOR. The activation of STAT3 protects
the liver and heart against IR injury [35,36], and inhibition of apoptosis is
one of its mechanisms in ATP depletion/recovery-induced TEC injury
model [37]. In the CHBP-treated group, enhanced STAT3phosphorylation
and decreased apoptotic cells were observed in the kidney, indicating
that CHBP suppressed apoptosis via STAT3 pathway activation.
In conclusion, the novel thioether-cyclized peptide CHBP demon-
strated much better stability than HBSP with less dose but longer
and stronger action both in vitro and in vivo. We proposed a potential
signaling pathway in which CHBP-induced autophagy in response to IR
via inhibition of mTORC1 and activation of mTOR2 was closely relatedto decreasing inﬂammation and apoptosis. This study suggested not
only the metabolically stable CHBP as a promising new therapy for the
treatment of kidney IR injury, but also the pivotal role of the AMPK/
Akt/mTOR signaling cascade in autophagy regulation of CHBP-mediated
renoprotection.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.09.001.
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